View ValuationReproCELL 将来の成長Future 基準チェック /06現在、 ReproCELLの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Dec 23Forecast breakeven date pushed back to 2026The analyst covering ReproCELL previously expected the company to break even in 2025. New forecast suggests losses will reduce by 56% per year to 2025. The company is expected to make a profit of JP¥100.0m in 2026. Average annual earnings growth of 96% is required to achieve expected profit on schedule.Breakeven Date Change • May 22Forecast to breakeven in 2025The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 48% to 2024. The company is expected to make a profit of JP¥30.0m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 04Forecast to breakeven in 2024The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of JP¥150.0m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 1 independent director (2 non-independent directors). Independent Outside Director Yoshiyuki Yamakawa was the last independent director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 14ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026.お知らせ • Mar 05Reprocell Launches Gmp Master Cell Bank Manufacturing For Clinical IpscsREPROCELL announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility, REPROCELL offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from StemRNA clinical seed iPSC manufacturing and StemEdit gene editing to GMP Master Cell Bank (MCB) production in compliance with FDA standards. By unifying these critical steps, REPROCELL enables cell therapy developers to accelerate IND submissions while reducing regulatory and manufacturing uncertainty. As part of this platform, the StemRNA Clinical iPSC Seed Clone – LLF-34-F3, derived from US sourced donor material, is supported by an active FDA Drug Master File (DMF). This clone has been expanded into a GMP MCB using FDA-compliant closed system processes. This off-the-shelf GMP iPSC MCB is available for commercial use, providing ready-to-use clinically validated starting material. For sponsors requiring European alignment, REPROCELL offers MCB/WCB manufacturing through its partner, Histocell. This service operates with a GMP certificate and authorization from the Spanish Agency for Medicines and Medical Devices (AEMPS) under European Medicines Agency (EMA) oversight. Donor sourcing and eligibility meet FDA, EMA, and PMDA requirements with full consent for therapeutic use. Footprint-free proprietary RNA reprogramming to generate StemRNA Clinical iPSC Seed Clones under FDA/EMA/PMDA requirements. US-generated StemRNA Clinical Seed Clones supported by an active FDA DMF. Genetic integrity and oncogenic risk assessment using whole-genome sequencing (WGS) for StemRNA Clinical Seed Clones. StemEdit clinical gene editing service, engineered for high on target efficiency with reduced off target activity and lower predicted immunogenicity. GMP MCB manufacturing in compliance with FDA or under EMA and PMDA authorization to manufacture. StemRNA Clinical iPSC Seed Clone – LLF-34-F3 is derived from a healthy O+ female US donor, fully consented for commercial and therapeutic use, and is homozygous at HLA-A and HLA-DPA1 loci enhancing its potential for allogeneic applications. The seed clone meets FDA, EMA and PMDA standards and is supported by a DMF while GMP MCB expansion uses FDA-compliant processes providing a traceable clinically ready starting material. REPROCELL also offers options of StemRNA Clinical iPSC Seed Clones from different donor profiles. This work was supported by a Commercialization Grant (no. 2024-MSCRFCO-6418) from the Maryland Stem Cell Research Fund (MSCRF).お知らせ • Dec 09ReproCELL Incorporated to Report Q3, 2026 Results on Feb 12, 2026ReproCELL Incorporated announced that they will report Q3, 2026 results on Feb 12, 2026お知らせ • Sep 02ReproCELL Incorporated to Report Q2, 2026 Results on Nov 13, 2025ReproCELL Incorporated announced that they will report Q2, 2026 results on Nov 13, 2025お知らせ • Jun 27ReproCELL Incorporated to Report Q1, 2026 Results on Aug 13, 2025ReproCELL Incorporated announced that they will report Q1, 2026 results on Aug 13, 2025お知らせ • May 14ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025.お知らせ • Mar 05ReproCELL Incorporated to Report Fiscal Year 2025 Results on May 14, 2025ReproCELL Incorporated announced that they will report fiscal year 2025 results on May 14, 2025お知らせ • Dec 10ReproCELL Incorporated to Report Q3, 2025 Results on Feb 13, 2025ReproCELL Incorporated announced that they will report Q3, 2025 results on Feb 13, 2025お知らせ • Aug 27ReproCELL Incorporated to Report Q2, 2025 Results on Nov 13, 2024ReproCELL Incorporated announced that they will report Q2, 2025 results on Nov 13, 2024Reported Earnings • Aug 19First quarter 2025 earnings released: JP¥0.84 loss per share (vs JP¥0.85 profit in 1Q 2024)First quarter 2025 results: JP¥0.84 loss per share (down from JP¥0.85 profit in 1Q 2024). Revenue: JP¥619.0m (up 11% from 1Q 2024). Net loss: JP¥75.0m (down 204% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Jun 06ReproCELL Incorporated to Report Q1, 2025 Results on Aug 13, 2024ReproCELL Incorporated announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • May 16Full year 2024 earnings released: JP¥0.36 loss per share (vs JP¥3.62 loss in FY 2023)Full year 2024 results: JP¥0.36 loss per share (improved from JP¥3.62 loss in FY 2023). Revenue: JP¥2.43b (down 18% from FY 2023). Net loss: JP¥31.0m (loss narrowed 90% from FY 2023). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.お知らせ • May 15ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024.New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$92.6m).New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: JP¥218m Forecast net loss in 2 years: JP¥57m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.4m market cap, or US$97.8m).お知らせ • Mar 02ReproCELL Incorporated to Report Fiscal Year 2024 Results on May 13, 2024ReproCELL Incorporated announced that they will report fiscal year 2024 results on May 13, 2024New Risk • Feb 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.2m market cap, or US$96.5m).Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥1.26 loss in 3Q 2023)Third quarter 2024 results: JP¥0.14 loss per share (improved from JP¥1.26 loss in 3Q 2023). Revenue: JP¥629.0m (down 2.8% from 3Q 2023). Net loss: JP¥12.0m (loss narrowed 89% from 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Breakeven Date Change • Dec 23Forecast breakeven date pushed back to 2026The analyst covering ReproCELL previously expected the company to break even in 2025. New forecast suggests losses will reduce by 56% per year to 2025. The company is expected to make a profit of JP¥100.0m in 2026. Average annual earnings growth of 96% is required to achieve expected profit on schedule.お知らせ • Dec 03ReproCELL Incorporated to Report Q3, 2024 Results on Feb 09, 2024ReproCELL Incorporated announced that they will report Q3, 2024 results on Feb 09, 2024Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥0.31 profit in 2Q 2023)Second quarter 2024 results: JP¥0.14 loss per share (down from JP¥0.31 profit in 2Q 2023). Revenue: JP¥591.0m (down 35% from 2Q 2023). Net loss: JP¥12.0m (down 146% from profit in 2Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.New Risk • Nov 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Aug 25ReproCELL Incorporated to Report Q2, 2024 Results on Nov 10, 2023ReproCELL Incorporated announced that they will report Q2, 2024 results on Nov 10, 2023Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.85 (vs JP¥0.51 in 1Q 2023)First quarter 2024 results: EPS: JP¥0.85 (up from JP¥0.51 in 1Q 2023). Revenue: JP¥556.0m (down 17% from 1Q 2023). Net income: JP¥72.0m (up 71% from 1Q 2023). Profit margin: 13% (up from 6.3% in 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.お知らせ • May 28ReproCELL Incorporated to Report Q1, 2024 Results on Aug 10, 2023ReproCELL Incorporated announced that they will report Q1, 2024 results on Aug 10, 2023Breakeven Date Change • May 22Forecast to breakeven in 2025The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 48% to 2024. The company is expected to make a profit of JP¥30.0m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.Reported Earnings • May 17Full year 2023 earnings released: JP¥3.62 loss per share (vs JP¥7.57 loss in FY 2022)Full year 2023 results: JP¥3.62 loss per share (improved from JP¥7.57 loss in FY 2022). Revenue: JP¥2.95b (up 32% from FY 2022). Net loss: JP¥305.0m (loss narrowed 47% from FY 2022). Revenue is forecast to stay flat during the next 2 years compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • May 14ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.26 loss per share (vs JP¥1.94 loss in 3Q 2022)Third quarter 2023 results: JP¥1.26 loss per share (improved from JP¥1.94 loss in 3Q 2022). Revenue: JP¥647.0m (up 30% from 3Q 2022). Net loss: JP¥107.0m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Dec 18ReproCELL Incorporated to Report Q3, 2023 Results on Feb 10, 2023ReproCELL Incorporated announced that they will report Q3, 2023 results on Feb 10, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥0.51 (vs JP¥1.70 loss in 1Q 2022)First quarter 2023 results: EPS: JP¥0.51 (up from JP¥1.70 loss in 1Q 2022). Revenue: JP¥666.0m (up 74% from 1Q 2022). Net income: JP¥42.0m (up JP¥164.0m from 1Q 2022). Profit margin: 6.3% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the next year, revenue is expected to shrink by 4.4% compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Jul 01ReproCELL Incorporated to Report Q1, 2023 Results on Aug 10, 2022ReproCELL Incorporated announced that they will report Q1, 2023 results on Aug 10, 2022お知らせ • May 18ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022.Reported Earnings • May 16Full year 2022 earnings released: JP¥7.57 loss per share (vs JP¥11.37 loss in FY 2021)Full year 2022 results: JP¥7.57 loss per share (up from JP¥11.37 loss in FY 2021). Revenue: JP¥2.23b (up 74% from FY 2021). Net loss: JP¥575.0m (loss narrowed 29% from FY 2021). Over the next year, revenue is expected to shrink by 12% compared to a 36% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 08ReproCELL Incorporated to Report Fiscal Year 2022 Results on May 13, 2022ReproCELL Incorporated announced that they will report fiscal year 2022 results on May 13, 2022Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: JP¥1.94 loss per share (up from JP¥4.10 loss in 3Q 2021). Revenue: JP¥499.0m (up 49% from 3Q 2021). Net loss: JP¥150.0m (loss narrowed 49% from 3Q 2021). Revenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 31%, compared to a 61% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥1.08 loss per share (vs JP¥2.20 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: JP¥607.0m (up 36% from 2Q 2021). Net loss: JP¥79.0m (loss narrowed 50% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Jun 18ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmOn June 17, 2021, ReproCELL Incorporated (JASDAQ:4978) closed the transaction.Breakeven Date Change • Jun 04Forecast to breakeven in 2024The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of JP¥150.0m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.お知らせ • Jun 02ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmReproCELL, Inc. (JASDAQ:4978) announced a private placement of 145,000 15th series warrants at a price of ¥122 per warrant with SMBC Nikko Securities Inc., Investment Arm for gross proceeds of ¥17,690,000 on June 1, 2021. The warrants are exercisable into 14,500,000 common shares of the company at an exercise price of ¥371 per share from June 18, 2021 to June 28, 2024. The warrants will be issued by third party allocation. The net proceeds from the transaction will be ¥15,862,000. The company will bear expenses for various expenses for the issuance including attorney fees, value calculation expense, and trust bank expense. The transaction has been approved by the board of directors of the company. The allotment date is December June 17, 2021.Reported Earnings • May 14Full year 2021 earnings released: JP¥11.37 loss per share (vs JP¥14.26 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.29b (up 7.3% from FY 2020). Net loss: JP¥812.0m (loss narrowed 20% from FY 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 04ReproCELL Incorporated to Report Fiscal Year 2021 Results on May 14, 2021ReproCELL Incorporated announced that they will report fiscal year 2021 results on May 14, 2021Is New 90 Day High Low • Feb 27New 90-day low: €2.94The company is down 5.0% from its price of €3.08 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 37%, compared to a 76% growth forecast for the Biotechs industry in Germany.Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥4.10 loss per share (vs JP¥3.18 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: JP¥335.0m (up 2.4% from 3Q 2020). Net loss: JP¥293.0m (loss widened 29% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Jan 26New 90-day high: €3.48The company is up 16% from its price of €3.00 on 28 October 2020. The German market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 12% over the same period.お知らせ • Nov 29ReproCELL Incorporated to Report Q3, 2021 Results on Feb 12, 2021ReproCELL Incorporated announced that they will report Q3, 2021 results on Feb 12, 2021Reported Earnings • Nov 13Second quarter 2021 earnings released: JP¥2.20 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: JP¥446.0m (up 45% from 2Q 2020). Net loss: JP¥157.0m (loss narrowed 24% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Nov 11New 90-day low: €2.88The company is down 15% from its price of €3.38 on 13 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 18% over the same period.お知らせ • Oct 10ReproCELL Incorporated to Report Q2, 2021 Results on Nov 12, 2020ReproCELL Incorporated announced that they will report Q2, 2021 results on Nov 12, 2020Reported Earnings • Oct 01First quarter earnings releasedOver the last 12 months the company has reported total losses of JP¥995.0m, with losses widening by 33% from the prior year. Total revenue was JP¥1.11b over the last 12 months, up 1.9% from the prior year.Is New 90 Day High Low • Sep 29New 90-day low: €2.92The company is down 18% from its price of €3.54 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ReproCELL は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:6RC - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20262,233-591-481-383N/A12/31/20252,519-324N/AN/AN/A9/30/20252,632-279-321-205N/A6/30/20252,834-126N/AN/AN/A3/31/20252,978103-896N/A12/31/20242,718-110N/AN/AN/A9/30/20242,599-195-356-200N/A6/30/20242,489-178N/AN/AN/A3/31/20242,426-31-202-11N/A12/31/20232,506-218N/AN/AN/A9/30/20232,524-313-274-142N/A6/30/20232,843-275N/AN/AN/A3/31/20232,953-305-301-140N/A12/31/20222,969-263N/AN/AN/A9/30/20222,821-306-144-46N/A6/30/20222,518-411N/AN/AN/A3/31/20222,234-575-294-246N/A12/31/20211,825-505N/AN/AN/A9/30/20211,661-648-514-440N/A6/30/20211,500-726N/AN/AN/A3/31/20211,286-812-712-648N/A12/31/20201,257-1,011N/AN/AN/A9/30/20201,249-945-802-673N/A6/30/20201,111-995N/AN/AN/A3/31/20201,199-1,016-829-689N/A12/31/20191,173-834N/AN/AN/A9/30/20191,114-809N/A-540N/A6/30/20191,090-750N/AN/AN/A3/31/20191,088-601N/A-554N/A12/31/20181,046-1,950N/AN/AN/A9/30/20181,018-1,965N/A-613N/A6/30/2018969-2,052N/AN/AN/A3/31/2018926-2,172N/A-636N/A12/31/20171,083-1,019N/AN/AN/A9/30/20171,187-759N/A-746N/A6/30/20171,202-765N/AN/AN/A3/31/20171,257-911N/A-775N/A12/31/20161,136-1,838N/AN/AN/A9/30/20161,043-2,150N/A-820N/A6/30/20161,069-2,199N/AN/AN/A3/31/20161,066-1,961N/A-614N/A12/31/20151,023-791N/AN/AN/A9/30/2015917-720N/A-769N/A6/30/2015743-518N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6RCの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6RCの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6RCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6RCの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6RCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6RCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 07:27終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ReproCELL Incorporated 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Akinori UedaGoldman Sachs
Breakeven Date Change • Dec 23Forecast breakeven date pushed back to 2026The analyst covering ReproCELL previously expected the company to break even in 2025. New forecast suggests losses will reduce by 56% per year to 2025. The company is expected to make a profit of JP¥100.0m in 2026. Average annual earnings growth of 96% is required to achieve expected profit on schedule.
Breakeven Date Change • May 22Forecast to breakeven in 2025The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 48% to 2024. The company is expected to make a profit of JP¥30.0m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 04Forecast to breakeven in 2024The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of JP¥150.0m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. 1 independent director (2 non-independent directors). Independent Outside Director Yoshiyuki Yamakawa was the last independent director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 14ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026ReproCELL Incorporated, Annual General Meeting, Jun 26, 2026.
お知らせ • Mar 05Reprocell Launches Gmp Master Cell Bank Manufacturing For Clinical IpscsREPROCELL announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility, REPROCELL offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from StemRNA clinical seed iPSC manufacturing and StemEdit gene editing to GMP Master Cell Bank (MCB) production in compliance with FDA standards. By unifying these critical steps, REPROCELL enables cell therapy developers to accelerate IND submissions while reducing regulatory and manufacturing uncertainty. As part of this platform, the StemRNA Clinical iPSC Seed Clone – LLF-34-F3, derived from US sourced donor material, is supported by an active FDA Drug Master File (DMF). This clone has been expanded into a GMP MCB using FDA-compliant closed system processes. This off-the-shelf GMP iPSC MCB is available for commercial use, providing ready-to-use clinically validated starting material. For sponsors requiring European alignment, REPROCELL offers MCB/WCB manufacturing through its partner, Histocell. This service operates with a GMP certificate and authorization from the Spanish Agency for Medicines and Medical Devices (AEMPS) under European Medicines Agency (EMA) oversight. Donor sourcing and eligibility meet FDA, EMA, and PMDA requirements with full consent for therapeutic use. Footprint-free proprietary RNA reprogramming to generate StemRNA Clinical iPSC Seed Clones under FDA/EMA/PMDA requirements. US-generated StemRNA Clinical Seed Clones supported by an active FDA DMF. Genetic integrity and oncogenic risk assessment using whole-genome sequencing (WGS) for StemRNA Clinical Seed Clones. StemEdit clinical gene editing service, engineered for high on target efficiency with reduced off target activity and lower predicted immunogenicity. GMP MCB manufacturing in compliance with FDA or under EMA and PMDA authorization to manufacture. StemRNA Clinical iPSC Seed Clone – LLF-34-F3 is derived from a healthy O+ female US donor, fully consented for commercial and therapeutic use, and is homozygous at HLA-A and HLA-DPA1 loci enhancing its potential for allogeneic applications. The seed clone meets FDA, EMA and PMDA standards and is supported by a DMF while GMP MCB expansion uses FDA-compliant processes providing a traceable clinically ready starting material. REPROCELL also offers options of StemRNA Clinical iPSC Seed Clones from different donor profiles. This work was supported by a Commercialization Grant (no. 2024-MSCRFCO-6418) from the Maryland Stem Cell Research Fund (MSCRF).
お知らせ • Dec 09ReproCELL Incorporated to Report Q3, 2026 Results on Feb 12, 2026ReproCELL Incorporated announced that they will report Q3, 2026 results on Feb 12, 2026
お知らせ • Sep 02ReproCELL Incorporated to Report Q2, 2026 Results on Nov 13, 2025ReproCELL Incorporated announced that they will report Q2, 2026 results on Nov 13, 2025
お知らせ • Jun 27ReproCELL Incorporated to Report Q1, 2026 Results on Aug 13, 2025ReproCELL Incorporated announced that they will report Q1, 2026 results on Aug 13, 2025
お知らせ • May 14ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025ReproCELL Incorporated, Annual General Meeting, Jun 24, 2025.
お知らせ • Mar 05ReproCELL Incorporated to Report Fiscal Year 2025 Results on May 14, 2025ReproCELL Incorporated announced that they will report fiscal year 2025 results on May 14, 2025
お知らせ • Dec 10ReproCELL Incorporated to Report Q3, 2025 Results on Feb 13, 2025ReproCELL Incorporated announced that they will report Q3, 2025 results on Feb 13, 2025
お知らせ • Aug 27ReproCELL Incorporated to Report Q2, 2025 Results on Nov 13, 2024ReproCELL Incorporated announced that they will report Q2, 2025 results on Nov 13, 2024
Reported Earnings • Aug 19First quarter 2025 earnings released: JP¥0.84 loss per share (vs JP¥0.85 profit in 1Q 2024)First quarter 2025 results: JP¥0.84 loss per share (down from JP¥0.85 profit in 1Q 2024). Revenue: JP¥619.0m (up 11% from 1Q 2024). Net loss: JP¥75.0m (down 204% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Jun 06ReproCELL Incorporated to Report Q1, 2025 Results on Aug 13, 2024ReproCELL Incorporated announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • May 16Full year 2024 earnings released: JP¥0.36 loss per share (vs JP¥3.62 loss in FY 2023)Full year 2024 results: JP¥0.36 loss per share (improved from JP¥3.62 loss in FY 2023). Revenue: JP¥2.43b (down 18% from FY 2023). Net loss: JP¥31.0m (loss narrowed 90% from FY 2023). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
お知らせ • May 15ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024ReproCELL Incorporated, Annual General Meeting, Jun 24, 2024.
New Risk • Mar 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$92.6m).
New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: JP¥218m Forecast net loss in 2 years: JP¥57m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥57m net loss in 2 years). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.4m market cap, or US$97.8m).
お知らせ • Mar 02ReproCELL Incorporated to Report Fiscal Year 2024 Results on May 13, 2024ReproCELL Incorporated announced that they will report fiscal year 2024 results on May 13, 2024
New Risk • Feb 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€89.2m market cap, or US$96.5m).
Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥1.26 loss in 3Q 2023)Third quarter 2024 results: JP¥0.14 loss per share (improved from JP¥1.26 loss in 3Q 2023). Revenue: JP¥629.0m (down 2.8% from 3Q 2023). Net loss: JP¥12.0m (loss narrowed 89% from 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Dec 23Forecast breakeven date pushed back to 2026The analyst covering ReproCELL previously expected the company to break even in 2025. New forecast suggests losses will reduce by 56% per year to 2025. The company is expected to make a profit of JP¥100.0m in 2026. Average annual earnings growth of 96% is required to achieve expected profit on schedule.
お知らせ • Dec 03ReproCELL Incorporated to Report Q3, 2024 Results on Feb 09, 2024ReproCELL Incorporated announced that they will report Q3, 2024 results on Feb 09, 2024
Reported Earnings • Nov 12Second quarter 2024 earnings released: JP¥0.14 loss per share (vs JP¥0.31 profit in 2Q 2023)Second quarter 2024 results: JP¥0.14 loss per share (down from JP¥0.31 profit in 2Q 2023). Revenue: JP¥591.0m (down 35% from 2Q 2023). Net loss: JP¥12.0m (down 146% from profit in 2Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
New Risk • Nov 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Aug 25ReproCELL Incorporated to Report Q2, 2024 Results on Nov 10, 2023ReproCELL Incorporated announced that they will report Q2, 2024 results on Nov 10, 2023
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.85 (vs JP¥0.51 in 1Q 2023)First quarter 2024 results: EPS: JP¥0.85 (up from JP¥0.51 in 1Q 2023). Revenue: JP¥556.0m (down 17% from 1Q 2023). Net income: JP¥72.0m (up 71% from 1Q 2023). Profit margin: 13% (up from 6.3% in 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
お知らせ • May 28ReproCELL Incorporated to Report Q1, 2024 Results on Aug 10, 2023ReproCELL Incorporated announced that they will report Q1, 2024 results on Aug 10, 2023
Breakeven Date Change • May 22Forecast to breakeven in 2025The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 48% to 2024. The company is expected to make a profit of JP¥30.0m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule.
Reported Earnings • May 17Full year 2023 earnings released: JP¥3.62 loss per share (vs JP¥7.57 loss in FY 2022)Full year 2023 results: JP¥3.62 loss per share (improved from JP¥7.57 loss in FY 2022). Revenue: JP¥2.95b (up 32% from FY 2022). Net loss: JP¥305.0m (loss narrowed 47% from FY 2022). Revenue is forecast to stay flat during the next 2 years compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • May 14ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023ReproCELL Incorporated, Annual General Meeting, Jun 22, 2023.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.26 loss per share (vs JP¥1.94 loss in 3Q 2022)Third quarter 2023 results: JP¥1.26 loss per share (improved from JP¥1.94 loss in 3Q 2022). Revenue: JP¥647.0m (up 30% from 3Q 2022). Net loss: JP¥107.0m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Dec 18ReproCELL Incorporated to Report Q3, 2023 Results on Feb 10, 2023ReproCELL Incorporated announced that they will report Q3, 2023 results on Feb 10, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥0.51 (vs JP¥1.70 loss in 1Q 2022)First quarter 2023 results: EPS: JP¥0.51 (up from JP¥1.70 loss in 1Q 2022). Revenue: JP¥666.0m (up 74% from 1Q 2022). Net income: JP¥42.0m (up JP¥164.0m from 1Q 2022). Profit margin: 6.3% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Over the next year, revenue is expected to shrink by 4.4% compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Jul 01ReproCELL Incorporated to Report Q1, 2023 Results on Aug 10, 2022ReproCELL Incorporated announced that they will report Q1, 2023 results on Aug 10, 2022
お知らせ • May 18ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022ReproCELL Incorporated, Annual General Meeting, Jun 24, 2022.
Reported Earnings • May 16Full year 2022 earnings released: JP¥7.57 loss per share (vs JP¥11.37 loss in FY 2021)Full year 2022 results: JP¥7.57 loss per share (up from JP¥11.37 loss in FY 2021). Revenue: JP¥2.23b (up 74% from FY 2021). Net loss: JP¥575.0m (loss narrowed 29% from FY 2021). Over the next year, revenue is expected to shrink by 12% compared to a 36% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. No independent directors (4 non-independent directors). External Auditor Akira Ishikawa was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 08ReproCELL Incorporated to Report Fiscal Year 2022 Results on May 13, 2022ReproCELL Incorporated announced that they will report fiscal year 2022 results on May 13, 2022
Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: JP¥1.94 loss per share (up from JP¥4.10 loss in 3Q 2021). Revenue: JP¥499.0m (up 49% from 3Q 2021). Net loss: JP¥150.0m (loss narrowed 49% from 3Q 2021). Revenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 31%, compared to a 61% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥1.08 loss per share (vs JP¥2.20 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: JP¥607.0m (up 36% from 2Q 2021). Net loss: JP¥79.0m (loss narrowed 50% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Jun 18ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmOn June 17, 2021, ReproCELL Incorporated (JASDAQ:4978) closed the transaction.
Breakeven Date Change • Jun 04Forecast to breakeven in 2024The analyst covering ReproCELL expects the company to break even for the first time. New forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of JP¥150.0m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
お知らせ • Jun 02ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment ArmReproCELL, Inc. (JASDAQ:4978) announced a private placement of 145,000 15th series warrants at a price of ¥122 per warrant with SMBC Nikko Securities Inc., Investment Arm for gross proceeds of ¥17,690,000 on June 1, 2021. The warrants are exercisable into 14,500,000 common shares of the company at an exercise price of ¥371 per share from June 18, 2021 to June 28, 2024. The warrants will be issued by third party allocation. The net proceeds from the transaction will be ¥15,862,000. The company will bear expenses for various expenses for the issuance including attorney fees, value calculation expense, and trust bank expense. The transaction has been approved by the board of directors of the company. The allotment date is December June 17, 2021.
Reported Earnings • May 14Full year 2021 earnings released: JP¥11.37 loss per share (vs JP¥14.26 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥1.29b (up 7.3% from FY 2020). Net loss: JP¥812.0m (loss narrowed 20% from FY 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 04ReproCELL Incorporated to Report Fiscal Year 2021 Results on May 14, 2021ReproCELL Incorporated announced that they will report fiscal year 2021 results on May 14, 2021
Is New 90 Day High Low • Feb 27New 90-day low: €2.94The company is down 5.0% from its price of €3.08 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.
Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 37%, compared to a 76% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥4.10 loss per share (vs JP¥3.18 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: JP¥335.0m (up 2.4% from 3Q 2020). Net loss: JP¥293.0m (loss widened 29% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Jan 26New 90-day high: €3.48The company is up 16% from its price of €3.00 on 28 October 2020. The German market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 12% over the same period.
お知らせ • Nov 29ReproCELL Incorporated to Report Q3, 2021 Results on Feb 12, 2021ReproCELL Incorporated announced that they will report Q3, 2021 results on Feb 12, 2021
Reported Earnings • Nov 13Second quarter 2021 earnings released: JP¥2.20 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: JP¥446.0m (up 45% from 2Q 2020). Net loss: JP¥157.0m (loss narrowed 24% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Nov 11New 90-day low: €2.88The company is down 15% from its price of €3.38 on 13 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 18% over the same period.
お知らせ • Oct 10ReproCELL Incorporated to Report Q2, 2021 Results on Nov 12, 2020ReproCELL Incorporated announced that they will report Q2, 2021 results on Nov 12, 2020
Reported Earnings • Oct 01First quarter earnings releasedOver the last 12 months the company has reported total losses of JP¥995.0m, with losses widening by 33% from the prior year. Total revenue was JP¥1.11b over the last 12 months, up 1.9% from the prior year.
Is New 90 Day High Low • Sep 29New 90-day low: €2.92The company is down 18% from its price of €3.54 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.